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Abstract
Background: The study examines the role of the volume of the effect compartment in simulations
of neuromuscular block (NMB) produced by nondepolarizing muscle relaxants.
Methods: The molar amount of the postsynaptic receptors at the motor end plates in muscle was
assumed constant; the apparent receptor concentration in the effect compartment is the ratio of
this amount and the volume arbitrarily assigned to the effect compartment. The muscle relaxants
were postulated to diffuse between the central and the effect compartment and to bind to the
postsynaptic receptors. NMB was calculated from the free concentration of the muscle relaxant in
the effect compartment.
Results: The simulations suggest that the time profiles of NMB and the derived pharmacokinetic
and pharmacodynamic variables are dependent on the apparent receptor concentration in the
effect compartment. For small, but not for large, volumes, times to peak submaximal NMB are
projected to depend on the magnitude of NMB and on the binding affinities.
Conclusion:  An experimental design to estimate the volume of the effect compartment is
suggested.
Background
In the majority of the pharmacokinetic-pharmacody-
namic (PK-PD) models proposed to simulate neuromus-
cular block (NMB) [1-3], the volume of the effect
compartment is postulated to be negligibly small or the
compartment is postulated to contain a negligibly small
amount of the muscle relaxant. The models simulate NMB
based on the concentration of the muscle relaxant in this
compartment using the equation of Hill. Binding of mus-
cle relaxants to the postsynaptic receptors at the motor
end plates is not considered. Because muscle relaxants
produce NMB by binding to these receptors, considera-
tion of the interaction of muscle relaxants with the recep-
tors represents a more realistic approach and an
advancement in simulations [4-6]. Donati and Meistel-
man [5] were the first to consider binding of muscle
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relaxants to the receptors. These investigators suggested
that the receptor concentration in the effect compartment
is 2.8·10-7 M, but the volume of the effect compartment
was assumed to be negligibly small. Given a fixed amount
of postsynaptic receptors, a finite receptor concentration
is not compatible with a negligibly small volume of the
effect compartment.
We decided to examine the role of the volume of the effect
compartment in a pharmacokinetic-pharmacodynamic
model for NMB and were interested in answering the fol-
lowing questions: (1) Is it necessary to postulate a negligi-
bly small amount of a muscle relaxant in the effect
compartment? (2) Do the projections from simulations
using a small or a large volume of the effect compartment
differ? If so, what are the differences? (3) Can the simula-
tions suggest an experimental design suitable to test
whether the volume of the effect compartment is negligi-
bly small or a large volume may be more appropriate?
Methods
General approach
(1) The amount of the postsynaptic receptors at the motor
end plates in muscle, in terms of mol per kg body weight,
was assumed constant and the receptors uniformly
diluted in the effect compartment. (2) The plasma con-
centrations of a hypothetical muscle relaxant after admin-
istration of an intravenous bolus dose, defined by an
arbitrary multiexponential equation, are labeled target
concentrations. In the simulations, the target plasma con-
centrations fulfill the role of the experimentally deter-
mined plasma concentrations. (3) A PK-PD model was
designed a priori to include an effect compartment of an
assigned volume. The pharmacokinetic parameters in the
model were defined by the postulate that the concentra-
tions in the central compartment (compartment1) fit the
target plasma concentrations. (4) The muscle relaxant dif-
fuses from the central to the effect compartment. (5) Phar-
macodynamic parameters were obtained from the
postulate that peak neuromuscular block from a bolus
ED50 dose occurs at 4.5 minutes after injection. The peak
concentration of the muscle relaxant in the effect com-
partment at this moment corresponds to the IC50 concen-
tration. (6) The relationship between NMB and the free
concentrations of the muscle relaxant in the effect com-
partment is defined by the Hill equation.
The target plasma concentrations
Muscle relaxant D was postulated to display linear phar-
macokinetics. The triexponential equation that defines
the time course of the molar amounts of the muscle relax-
ant in plasma is given by (braces indicate molar
amounts):
Here, N, O, and P (P = 1 - N - O) are fractions of the dose
that are eliminated from plasma with the first order rate
constants  λN,  λO, and λP, respectively. The dose is in
mol·kg-1. Division of the equation by VC, VC expressed in
L·kg-1, converts the amounts in plasma to molar concen-
trations. VC represents the volume of the space into which
the muscle relaxant is uniformly diluted at time t = 0, i.e.,
at the moment of bolus intravenous injection.
The values assigned to the parameters in the triexponen-
tial equation were based on the following postulates: For
the hypothetical muscle relaxant D, VC approximates the
volume of plasma and VSS, the volume of distribution at
steady state, approximates the volume of the extracellular
space. The dose that produces NMB50, i.e., ED50, is
defined by the postulate that the concentration in plasma
at 4.5 min after bolus intravenous injection is [D]plasma =
IC50. The definition of IC50 is provided below. The fol-
lowing values satisfy these requirements:
N = 0.71; O = 0.192; P = 0.098
λN = 1.3 min-1; λO = 0.31 min-1; λP = 0.0231 min-1
VC = 0.044 L·kg-1 VSS = 0.28 L·kg-1
Compartmental interpretation of the triexponential decay
of the plasma concentrations yields the following param-
eters for the standard 3-compartment pharmacokinetic
model assuming a mammillary arrangement of the com-
partments and elimination only from compartment1[7]:
V1 = VC = 0.044 L·kg-1 k10 = 0.1848 min-1
k12 = 0.3771 min-1 k21 = 0.5581 min-1
k13 = 0.4229 min-1 k31 = 0.0902 min-1
Estimation of the receptor amount
The molar amount of receptors per kg body weight was
estimated based on the following assumptions: One hun-
dred g of muscle is represented as a cube with side length
of 4.64 cm, i.e., specific density of muscle ~ 1. There is 430
g muscle per kg body weight. The muscle fibers are
densely packed cylinders with the diameter of 50 µm and
the length of 4.64 cm (928 rows × 928 columns of fibers
in a cross section perpendicular to the length of the fib-
ers). Each muscle fiber has one motor end plate with
2.1·107 receptors at each end plate [8,9].
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The PK-PD Model
The pharmacokinetic model consists of four compart-
ments: the central (compartment1), two peripheral
(compartment2 and compartment3), and the effect com-
partment in mammillary arrangement with elimination
from the central compartment. The model is defined in
terms of the amounts of the muscle relaxant present in
each compartment and the amount eliminated from the
body. Transport between the central and the effect com-
partment is defined as diffusion according to the concen-
tration gradient of the free muscle relaxant in both
compartments. As a result, at the moment when the free
muscle relaxant attains the peak concentration in the
effect compartment and there is no net transport between
the compartments (steady state), the concentrations in
the two compartments are equal. In the model, this con-
straint necessitates that the transport rate constant into the
effect compartment, k1e, be defined in terms of the trans-
port rate constant from the effect to the central compart-
ment, ke1. Hence, k1e  = (Ve/V1)·ke1, where Ve and V1
represent the volumes of the effect and the central com-
partments, respectively. The volume of the central com-
partment is known (V1  ≈ V C  in the triexponential
function). The volume of the effect compartment was
assigned different values. Hence, the amounts of D in the
central and the effect compartments may be converted to
concentrations. Compartment2  and compartment3  are
defined only in terms of the amounts present in them.
The amount of receptors in the effect compartment is con-
stant and independent of the volume assigned to the
effect compartment. A small assigned volume results in a
high receptor concentration, while the concentration is
low in the large effect compartment.
For an assigned volume of the effect compartment (Ve),
the pharmacokinetic parameters in the PK-PD model were
estimated in a two-step procedure. In the first step, the
parameter ke1  was obtained using the following con-
straints: dose = ED50, the amounts in plasma as defined
by the triexponential equation, and the maximal NMB =
50% attained at 4.5 min after administration of the mus-
cle relaxant. In the second step, the parameters V1, k10, k12,
k21, k13, and k31 were estimated using the following con-
straints: dose = ED50 and ke1 fixed to the value obtained
in the first step. The parameters were fitted by minimizing
the sum of squared differences between the logarithms for
the calculated concentrations in compartment1 and the
target concentrations in plasma. The evaluations were car-
ried out at 250 time points from t = 0 to t = 25 min and at
50 points for t = 25 to t = 50 min after administration.
Goodness-of fit was expressed as the coefficient of varia-
tion (CV in % 1) of the differences between the two time
profiles.
Interaction between the muscle relaxant and the postsyn-
aptic receptors was defined in terms of the association, kas-
soc, and dissociation, kdis, rate constants. We assumed that
each receptor possesses only a single binding site for the
muscle relaxant. The ratio kdis/kassoc defines the equilib-
rium dissociation constant, KD. The inverse of KD defines
the affinity of the receptors for the muscle relaxant.
The values of all the mentioned parameters are listed in
Table 1. The set of five ordinary differential equations
defining the amounts of the muscle relaxant in the four
compartments and the amount of the complex with the
receptors in the effect compartment is presented in the
Appendix.
Table 1: Pharmacokinetic and pharmacodynamic parameters for the PK-PD model. The volume of the effect compartment (Ve) was 
postulated to be either small (SMALL) or large (LARGE).
Parameter Unit SMALL LARGE
ED50 mol·kg-1 2.2325·10-7
V1 L·kg-1 0.0440 0.0434
k10 min-1 0.1847 0.1795
k12 min-1 0.3769 0.3574
k21 min-1 0.5587 0.7663
k13 min-1 0.4226 0.1981
k31 min-1 0.0909 0.0581
kassoc M-1·min-1 2.4·1010
{R}total mol·kg-1 1.2921·10-10
Ve L·kg-1 4.4·10-5 9.23·10-2
ke1 min-1 0.6159 0.1477
[R]total M2 . 9 3 6 7 · 1 0 -6 1.4·10-9
Onset time min 4.50Theoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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Calculation of NMB
The intravenous bolus dose of the muscle relaxant
required to produce a half-maximal NMB, NMB50, is
labeled ED50. We postulated that NMB50 is attained at
4.5 min after the bolus injection. The peak concentration
of the free muscle relaxant in the effect compartment
established by ED50 is IC50. At 4.5 min after injection,
[D]plasma = peak [D]e = IC50. The fractional receptor occu-
pancy by the muscle relaxant (Occ) at NMB50 is labeled
OccNMB50 and assigned a value of 0.875 [10]. Because KD
= [D]e·(1 - Occ)/Occ, and at NMB50 [D]e = IC50 and Occ
= OccNMB50 = 0.875, it follows that IC50 = 7·KD.
Neuromuscular block (NMB) was calculated using the
Hill equation, the free concentrations of the muscle relax-
ant in the effect compartment, [D]e, and two parameters:
γ and IC50 (γ = 4 and IC50 = 7·KD, Eq 1 in Appendix).
To describe quantitatively the simulated NMB as a func-
tion of doses used to establish the peak concentrations in
the effect compartment, the values for NMB calculated
from peak [D]e were plotted as a function of doses of the
muscle relaxant. A modified equation of Hill (Eq. 2,
Appendix) was fitted to these points using the program
TableCurve2D from SPSS, Chicago, IL, and the fitted esti-
mates of the exponent γf and ED50f are reported.
All calculations were performed independently using the
programs MATHEMATICA (version 5.1) from Wolfram
Research, Inc., Champaign, IL, MULTIFIT and PKPDFIT
written by J.H. Proost, and MATLAB (version
6.1.0.450(R12.1)) from The Mathworks Inc., Natick, MA.
Results
The estimated total molar amount of receptors at the
motor end plates in muscles is {R}total = 1.2921·10-10
mol·kg-1. Receptor concentration in the effect compart-
ment is the ratio of this amount and the volume assigned
to the effect compartment.
Simulations with a small or a large volume assigned to the 
effect compartment
For the initial simulations, Ve was assigned the value of
0.001·VC, i.e., Ve = 4.4·10-5 L·kg-1 [11], for the small and
0.0923 L·kg-1 for the large effect compartment. The latter
approximates the volume of the interstitial space in mus-
cle. Receptor concentrations in the effect compartment
were: [R]total = 2.94·10-6 M and 1.4·10-9 M for the small
and large volume, respectively. The hypothetical muscle
relaxant D was assigned KD = 1·10-7 M. The assignment
defined ED50 as ED50 = 2.23·10-7 mol·kg-1. Optimal
estimates of the pharmacokinetic parameters, including
ke1, were obtained as described in the Methods section.
The target amounts of the muscle relaxant in plasma and
those estimated in compartment1 as well as the amounts
in the small and the large effect compartments are graph-
ically presented in the upper panel of Figure 1. The three
curves for the amounts in plasma overlap. The good fit of
the amounts in compartment1 to the target amounts in
plasma is evident from the small values of the coefficient
of variation, 0.0007% for the small and 0.7% for the large
volume of the effect compartment. The peak free amount
of D in the small effect compartment constitutes a small
fraction of ED50, 1.38·10-4. On the other hand, the peak
free amount of D in the large effect compartment accounts
for a sizable fraction of ED50, 0.289 (upper panel in Fig-
ure 1). The PK-PD model that includes a large effect com-
partment requires intercompartmental transport rate
constants different from those for the small volume of the
effect compartment (Table 1). The peak receptor occu-
pancy, Occ = OccNMB50 = 0.875, and the peak [D]e = IC50
= 7·KD, were attained at 4.50 min for either volume of the
effect compartment. Hence, for both volumes the simu-
lated peak NMB = NMB50 and occurs at 4.5 min after
injection, but the time course of NMB is different between
the small and large volumes of the effect compartment
(lower panel in Figure 1). To reach the respective peaks at
4.50 min after the injection required ke1 that was approx-
imately four times higher for the small than for the large
effect compartment (Table 1).
The calculations were verified by calculating the sum of
the amounts in the four compartments plus the amount
eliminated from the body. For all times between 0 and 50
min after injection, the sum was equal to ED50. Expressed
as fractions of the administered dose (= ED50), the peak
amounts in compartment2 and compartment3 and the
times after injection when the peaks were attained are for
the small volume of the effect compartment 0.199 at 1.6
min and 0.483 at 7.3 min, respectively. For the large vol-
ume, the corresponding values are 0.158 at 1.3 min and
0.268 at 11.9 min.
Two additional observations were made during these sim-
ulations. First, exclusion of the small effect compartment
from the PK-PD model only minimally influences the fit
of the amounts in compartment1 to the target plasma
amounts. The result is not unexpected, because the inter-
compartmental transport rate constants (microconstants)
in the model with a small volume of the effect compart-
ment (Table 1) are close to those in the standard 3-com-
partment model. Second, when the effect compartment in
the PK-PD model was postulated not to contain the recep-
tors, i.e., {R}total = 0, identical values of ke1 establish the
peak free amount of D in the respective effect compart-
ment at identical times (data not presented).
Based on the derived pharmacokinetic rate constants,
NMB was simulated with different doses of D. One thou-
sand points were selected for a 10-fold increase in doses.Theoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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NMB was calculated with the peak free concentrations of
D in the effect compartment using Eq 1 in the Appendix
(γ = 4 and IC50 = 7·10-7 M). The relationship between
NMB and the doses that produced the peak concentra-
tions differed between the models (upper panel in Figure
2 for NMB = 0.05 to NMB = 0.95, i.e., NMB05 to NMB95).
To obtain a quantitative estimate for the difference, equa-
tion of Hill (Eq 2) was fitted to both sets of points to
describe the relationship between NMB and the injected
doses. The fit was excellent for both sets (r2 > 0.9999, the
number of points, n, = 381 for the small and n = 641 for
the large volume of the effect compartment). The 95%
confidence interval (95%CI) for the fitted γf was 6.819 to
Upper panel: The amounts of muscle relaxant D (KD = 1·10-7  M) in plasma and compartment1 and the free amounts in the  effect compartment assigned a small (Ve = 4.4·10-5 L·kg-1) or a  large (Ve = 9.23·10-2 L·kg-1) volume Figure 1
Upper panel: The amounts of muscle relaxant D (KD = 1·10-7 
M) in plasma and compartment1 and the free amounts in the 
effect compartment assigned a small (Ve = 4.4·10-5 L·kg-1) or a 
large (Ve = 9.23·10-2 L·kg-1) volume. All the amounts are nor-
malized to the injected dose (= ED50 = 2.23·10-7 mol·kg-1). 
Solid and dashed lines indicate the amounts contained in the 
small and the large effect compartment, respectively. Filled 
circles denote the target amounts in plasma defined by the 
triexponential function. The three curves for the amounts in 
plasma overlap. The estimates were obtained at 0.1 min 
intervals. Lower panel: Time course of the neuromuscular 
block (NMB) by ED50 of the muscle relaxant D. NMB was 
calculated using Eq 1 (Appendix), [D]e for the small and large 
volume of the effect compartment presented in the upper 
panel, and by setting γ = 4.0 and IC50 = 7·10-7 M. The lines 
are identical to those in the upper panel for the small and 
large volume of the effect compartment.
Upper panel: Neuromuscular block (NMB) calculated as a  function of the peak concentrations of muscle relaxant D in  the effect compartment using Eq 1 presented in the Appen- dix (γ = 4.0 and IC50 = 7·10-7 M) Figure 2
Upper panel: Neuromuscular block (NMB) calculated as a 
function of the peak concentrations of muscle relaxant D in 
the effect compartment using Eq 1 presented in the Appen-
dix (γ = 4.0 and IC50 = 7·10-7 M). The doses presented along 
the abscissa refer to the doses that established the peak con-
centrations. The range of NMB is from NMB05 to NMB95. 
One thousand logarithmically equidistant values were used 
for a 10-fold increase in doses. The volumes of the effect 
compartment and the lines are identical to those presented 
in Figure 1. Lower panel: Onset times as a function of the mag-
nitude of NMB. Onset times are defined as the times after 
the bolus intravenous injection of muscle relaxant D needed 
to establish peak NMB, from NMB05 to NMB95. Other 
details are identical to those in the upper panel.Theoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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6.838 for the small and 4.0040 to 4.0041 for the large
effect compartment. The 95%CI for the fitted ED50f were
(2.235 to 2.236)·10-7  mol·kg-1  and (2.23256 to
2.23258)·10-7 mol·kg-1, respectively.
The onset times for NMB05 to NMB95 differed between
the models assigned different volumes of the effect com-
partment (lower panel in Figure 2). The model with the
large effect compartment projected that the onset times
were nearly independent of the magnitude of NMB. The
model incorporating a small volume of the effect com-
partment projected an inverse relationship between the
onset times and the magnitudes of NMB. For NMB <
NMB50, the onset times were longer, and for NMB >
NMB50 the onset times were shorter than those projected
by the model with a large effect compartment.
Simulations with different volumes assigned to the effect 
compartment using ED50
Next, the influence of the volume assigned to the effect
compartment was examined systematically. The volumes
varied from 1·10-6 to 1·10-1 L·kg-1 (11 logarithmically
equidistant values). The pharmacokinetic parameters,
including ke1, were estimated as previously stipulated, i.e.,
ED50 dose establishes peak receptor occupancy = Occ875
and peak [D]e = IC50 at 4.5 min after injection. The coef-
ficient of variation for the fit of the concentrations of D in
compartment1 to the target plasma concentrations was CV
= 0.84% for the largest and = 0.0006% for the smallest
volume. The values for ke1 as a function of the assigned
volumes, estimated with ED50 and using the same muscle
relaxant (KD = 1·10-7 M), are presented in the upper panel
of Figure 3. The results demonstrate that ke1 increases
markedly for the smaller values of Ve. The relative
amounts of D bound to the receptors, the amounts free in
the effect compartment, and the ratio of the bound to the
total amount in the effect compartment with ED50 show
(lower panel in Figure 3) that for all volumes the amounts
of D bound to the receptors are constant. For smaller vol-
umes the bound amounts make up nearly all of D present
in the effect compartment, while for larger volumes the
total amount of D is nearly completely accounted for by
the free amount.
Simulations using different volumes and different doses
We used the set of pharmacokinetic parameters obtained
for each assigned volume, but now varied the dose using
1000 values for a ten-fold increase. The results are pre-
sented in Figure 4. Increasing doses increase the peak free
concentrations of D for each volume of the effect com-
partment (upper panel in Figure 4). The increase is
steepest for the smallest volume and the slopes decrease
for the larger assigned volumes. The estimated peak free
concentrations of D in the effect compartment were used
to calculate NMB (IC50 = 7·10-7 M and γ = 4, Eq 1 in
Appendix). The values of NMB from NMB05 to NMB95 as
calculated using [D]e were plotted against the injected
doses separately for each assigned volume, similarly to the
results presented in the upper panel of Figure 2. The mod-
ified equation of Hill (Eq 2, Appendix) was fitted to each
of these 11 sets of points to define NMB as a function of
the injected doses. The fit was excellent (r2 > 0.9996 for n
between 314 to 641 points). The fitted values of γf are pre-
sented in the lower panel in Figure 4. The values increase
markedly for smaller volumes. The 95%CI for the eleven
fitted estimates of ED50f  varied between (2.225 to
2.226)·10-7 mol·kg-1 for the smallest and (2.25720 to
Upper panel: Values estimated for the transport rate constant  between the effect and the central compartment, ke1, as a  function of the volume assigned to the effect compartment,  Ve Figure 3
Upper panel: Values estimated for the transport rate constant 
between the effect and the central compartment, ke1, as a 
function of the volume assigned to the effect compartment, 
Ve. The dose of the muscle relaxant D = ED50 = 2.23·10-7 
mol·kg-1 and KD = 1·10-7 M. Lower panel: Amounts of the mus-
cle relaxant D (left Y-axis) bound to the receptors (filled 
upright triangles) and the amounts free (filled diamonds). The 
amounts are normalized to the injected dose presented in 
the upper panel. The ratio of the bound to the total amounts 
(empty circles; total = bound + free; right Y-axis) in the effect 
compartment is presented as a function of the volume 
assigned to the effect compartment.Theoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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2.25722)·10-7 mol·kg-1 for the largest volume. These sim-
ulations permitted us to estimate the times to NMB05 and
NMB95 (onset times). The results are presented in the
lower panel of Figure 4. Onset times for NMB05 and
NMB95 differ widely for the small volumes, but the differ-
ences progressively decrease for larger volumes of the
effect compartment. The onset times for NMB05 and
NMB95 are nearly identical for the largest assigned
volume.
Simulations with different binding affinities assigned to 
muscle relaxants
The PK-PD model was also tested with two additional
muscle relaxants using the previously defined small and
large volumes of the effect compartment. One muscle
relaxant, D2, was assigned a 10 times lower affinity for the
binding sites at the receptors, KD2 = 1·10-6 M. The other,
D3, was assigned a 10 times higher affinity, KD3 = 1·10-8
M. The assignments changed the respective kdiss, but not
kassoc. Two series of simulations were performed. In the
first series, all the pharmacokinetic constants, including
ke1, were those defined previously for either the small or
the large volume of the effect compartment and for the
muscle relaxant with KD = 1·10-7 M (Table 1). A 100-fold
increase in affinities was projected to require 16.3 times
lower ED50 for the small volume (ED50 = 1.144·10-6
mol·kg-1 for D2 and ED50 = 7.018·10-8 mol·kg-1 for D3),
but a 98.9 times lower ED50 (ED50 = 2.230·10-6 mol·kg-
1 for D2 and ED50 = 2.255·10-8 mol·kg-1 for D3) for the
model with a large volume of the effect compartment. For
the small effect compartment, the times to reach NMB50
were 1.82 min for D2 and 34.74 min for D3. In the model
with a large effect compartment, the times to NMB50 dif-
fered only minimally, from 4.50 min for D2 to 4.54 min
for D3.
In the second series of simulations, we postulated that
ED50 of either D2 or D3 produces NMB50 at 4.5 min after
injection using either the small or the large volume of the
effect compartment. The doses producing NMB50 were
related to the assigned KD values, i.e., ED50 = 2.2325·10-
6 mol·kg-1 for D2 and ED50 = 2.2325·10-8 mol·kg-1 for
D3. These doses establish plasma concentrations at 4.5
min [D]plasma = IC50 = 7·KD = peak [D]e. In the model
containing a small volume of the effect compartment, the
postulate was satisfied by ke1 = 0.196 min-1 for D2 and ke1
= 4.710 min-1 for D3. For the large volume, the estimates
of ke1 were 0.1475 min-1 for D2 and 0.1498 min-1 for D3.
Discussion
The simulations suggest that the volume of the effect com-
partment per se is not the critical parameter in a PK-PD
model for nondepolarizing muscle relaxants. If the effect
compartment is postulated to be void of the postsynaptic
receptors, then the peak concentration of free muscle
relaxant in this compartment is attained at identical times
using identical transport rate constant ke1 for any volume
Upper panel: The peak free concentrations of muscle relaxant  D in the effect compartment calculated with variable doses of  D as a function of the volumes assigned to the effect  compartment Figure 4
Upper panel: The peak free concentrations of muscle relaxant 
D in the effect compartment calculated with variable doses of 
D as a function of the volumes assigned to the effect com-
partment. The assigned volumes were: 1·10-6, 3.16·10-6, 1·10-
5, 3.16·10-5, 1·10-4, 3.16·10-4, 1·10-3, 3.16·10-3, 1·10-2, 3.16·10-
2, and 1·10-1 L·kg-1. The bold solid and the dotted lines indi-
cate the lowest and the highest assigned volumes, respec-
tively. Concentrations for the intermediate volumes are 
indicated in sequence by thin solid lines. The three dashed 
lines parallel with the X-axis represent the free concentra-
tion of D for NMB95 (IC95, upper line), for NMB50 (IC50, 
middle line) and for NMB05 (IC05, lower line). The concen-
trations for IC05 and IC95 were calculated based on γ = 4.0 
(Eq 1, Appendix). Lower panel: Times to NMB05 (open cir-
cles) and NMB95 (filled circles, left Y-axis) as a function of 
the volumes assigned to the effect compartment, Ve. Neu-
romuscular block was calculated using Eq 1 (IC50 = 7·10-7 M, 
γ = 4) and the peak free concentrations of D presented in 
the upper panel. The values of the exponent γf (filled dia-
monds, right Y-axis) were obtained by fitting Eq 2 to the cal-
culated NMB.Theoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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of the effect compartment. These conclusions agree with
those obtained from PK-PD models assuming a negligibly
small volume of the effect compartment and not taking
into account binding of a muscle relaxant to the postsyn-
aptic receptors [1-3]. However, NMB is produced not by
the free molecules of muscle relaxants in the effect com-
partment, but by the molecules bound to the postsynaptic
receptors at the motor end plates. Therefore, considera-
tion of binding of muscle relaxants to the postsynaptic
receptors in the effect compartment is advantageous in
PK-PD modeling. The present simulations confirm the
conclusion from the reports [4-6] that the receptor con-
centration in the effect compartment is a critical
parameter in PK-PD modeling. The predictions from our
simulations assuming a low or a high receptor concentra-
tion differ with respect to (1) the onset times to the peak
but submaximal neuromuscular block for a single muscle
relaxant (lower panel in Figure 2), (2) the time course of
NMB using ED50 (lower panel in Figure 1), (3) the shape
of the NMB-versus-dose curves (upper panel in Figure 2),
(4) the estimates of ke1 (Table 1 and upper panel in Figure
3), and (5) the estimates of ED50 and the onset times as a
function of affinities assigned to the muscle relaxants for
binding to the receptors (D2 and D3, Results).
In the aforementioned models [4-6], receptor concentra-
tion was an explicit model parameter. In contrast, the
present model defines the receptor concentration as the
ratio between the constant amount of postsynaptic recep-
tors and the variable volume assigned to the effect com-
partment. This approach allows PK-PD modeling without
the constraint of a negligibly small effect compartment.
The earlier models taking into account receptor concentra-
tion [4-6] assumed a negligibly small volume of the effect
compartment. Given a fixed amount of postsynaptic
receptors, a finite receptor concentration is not compati-
ble with the negligibly small volume of the effect com-
partment. This is an inherent weakness of such models.
A compartment is defined by Jacquez [12] as "an amount
of a material that acts kinetically like a distinct,
homogenous amount". This is the reason that the five
equations defining the transport and the distribution of a
muscle relaxant in the body (Appendix) were formulated
in terms of amounts rather than concentrations. The total
amount of a drug in the body is represented by two, three,
or more such compartments. The necessity to invoke
more than a single compartment arises from the physico-
chemical properties of the drug in relation to those struc-
tures in the body that prevent drug's uniform dilution.
Anatomical structures and/or physiologic processes repre-
sent these barriers. For muscle relaxants, small
hydrophilic cations with MW < 1000 da, the principal
barriers are the capillary wall and the cellular membranes.
It seems plausible to postulate that muscle relaxants dif-
fuse through the pores in the capillary wall into the sur-
rounding interstitial spaces. Diffusion across the cellular
membranes is very unlikely due to the high hydrophilicity
of the molecules. Therefore and as a first approximation,
muscle relaxants remain diluted in a space limited to
plasma and the interstitial space. The pharmacokinetic
compartments for muscle relaxants likely represent the
amounts of muscle relaxants in plasma and the interstitial
spaces of different tissues.
In the muscle, muscle relaxants diffuse throughout the
interstitial space, including the synaptic clefts at the motor
end plates. There are no anatomical barriers between the
interstitial space in muscle and the synaptic clefts to pre-
vent diffusion of muscle relaxants into the synaptic clefts
[13]. These considerations qualify the interstitial space in
muscle, including the synaptic spaces, as a single
pharmacokinetic compartment. The volume of the inter-
stitial space in muscle defines the volume of this
compartment.
Due to the presence of the postsynaptic receptors in the
synaptic clefts, the
compartment represents the effect compartment for mus-
cle relaxants. The functional receptors are immobile and
are located exclusively within the synaptic clefts. Hence,
interaction between the receptors and the free molecules
of a muscle relaxant occurs due to diffusion of the free
molecules of the muscle relaxant to the receptors. In
effect, interaction between the two partners may be repre-
sented as proceeding in a space common to both, i.e., the
interstitial space in muscle. Volume of this space defines
the volume of the effect compartment, Ve. We suggest that
the apparent or the effective concentration of the postsyn-
aptic receptors for the interaction with muscle relaxants is
the ratio of the amount of receptors and the volume of
interaction, [R]total = {R}total/Ve.
Transport of a drug between two compartments is repre-
sented in a standard pharmacokinetic model by two first-
order rate constants. A modification of this approach is
needed, if the transport is assumed to proceed via diffu-
sion. Occurrence of a peak amount in a non-central com-
partment suggests that at that moment there is no net
transport. The postulate of transport via diffusion implies
that the concentration of a muscle relaxant in the central
and the peak concentration in the effect compartment are
identical at that moment. In the simulations, the transport
rate constant out of the effect compartment into
compartment1 is represented by the symbol ke1. The rate
constant in the opposite direction, k1e, is expressed as a
function of ke1,  viz., k1e = ke1·(Ve/V1). The expression
results from the postulate that the transport occurs via dif-
fusion. We suggest that ke1 may be interpreted as the ratioTheoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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of the plasma flow to the muscle and the volume of the
interstitial space in muscle. For the adductor pollicis mus-
cle and assuming plasma flow to the forearm or the hand
of 0.9 to 4.7 mL·min-1·(100 g muscle)-1 [14] and the vol-
ume of the interstitial space in muscle of 15 to 22
mL·(100 g muscle)-1, the value of the transport rate
constant ke1 may be estimated to between 0.041 and
0.313 min-1.
The postulate seems plausible that the molar amount of
the postsynaptic receptors is a physiologic constant. The
value of the constant may be 10 times lower or 10 times
higher than the assigned value (Table 1) without mark-
edly altering the results of the simulations. The postulate
of a constant amount of postsynaptic receptors permits
the definition of the apparent receptor concentration in
the effect compartment via the relationship [R]total  =
{R}total/Ve.
The results of the simulations demonstrate that a PK-PD
model may be constructed for a wide range of volumes
assigned to the effect compartment. We examined Ve from
1·10-6 to 1·10-1 L·kg-1and the corresponding apparent
concentrations of the receptors. In general, smaller
volumes require higher values of ke1 (upper panel in Fig-
ure 3), are associated with smaller total amounts of the
muscle relaxant in the effect compartment and larger frac-
tions of the muscle relaxant in the bound form (lower
panel in Figure 3). The smaller volumes are compatible
with the intercompartmental transport rate constants
close to those in the standard 3-compartment pharmacok-
inetic model. For volumes < 1·10-3 L·kg-1, the onset times
of submaximal NMB are negatively correlated with the
magnitude of NMB (lower panels in Figures 2 and 4). The
onset times are also markedly dependent on the values
assigned to the equilibrium dissociation constants for
binding of the muscle relaxants to the receptors (muscle
relaxants D2 and D3), higher affinities associated with pro-
longed onset times. All these findings change for Ve >
1·10-3 L·kg-1 and the receptors concentrations < 1·10-7 M
(Figures 3 and 4). Specifically, the values of the rate con-
stant ke1 become smaller and relatively independent of the
assigned volumes (upper panel in Figure 3), the differ-
ences between onset times for NMB05 and NMB95 pro-
gressively disappear (lower panel in Figure 4), the
affinities do not influence the onset to NMB50, and ED50
doses are proportional to KD (muscle relaxants D2 and D3,
Results). It appears as if the value of Ve of about 1·10-3
L·kg-1 and the receptor concentration ~ 1·10-7 M repre-
sent the critical threshold for the difference between a
"small" and a "large" volume of the effect compartment.
The results of the simulations reveal a difference in the
slopes of the NMB curves when evaluated as a function of
the injected doses of a muscle relaxant. As in the available
pharmacodynamic models, NMB in the proposed model
was calculated using the peak free concentration of a mus-
cle relaxant in the effect compartment and two constants:
γ and IC50 (Eq 1, Appendix). When the NMB, calculated
using peak [D]e, was plotted as a function of the doses that
produced these peak concentrations in the effect compart-
ment, the fitted value of γf (Eq 2, Appendix) was larger
than γ used in the calculation of NMB from [D]e (upper
panel in Figure 2 and lower panel in Figure 4) and the fit-
ted values of γf increase progressively for smaller volumes
assigned to the effect compartment (lower panel in Figure
4). For volumes > 10-3  L·kg-1, the fitted values of γf
approach the value of γ used in the calculations of NMB
from [D]e (lower panel, Figure 4). The difference is due to
the relationship between the peak concentrations of the
free muscle relaxant in the effect compartment and the
injected doses (upper panel in Figure 4). For volumes <
10-3 L·kg-1, the peak concentrations increase rapidly with
increasing doses. The steeper slope implies that the differ-
ence in doses producing IC05 and IC95, corresponding to
NMB05 and NMB95, respectively, is smaller the smaller
the volume assigned to the effect compartment. The nar-
rower spread of these doses leads, in turn, to higher fitted
values of γf when NMB is represented as a function of the
injected dose. To summarize, if Ve < 10-3 L·kg-1, then a cor-
relation of NMB to the doses needed to establish the peak
concentrations requires fitted values for γf higher than the
value of γ used in calculating NMB from [D]e. For Ve > 10-
3 L·kg-1, the estimates of the fitted γf approach the value of
γ used in calculating NMB as a function of [D]e. Therefore,
a comparison of γ, estimated in a PK-PD model and based
on [D]e, with γf, obtained experimentally in a NMB-versus-
dose study, provides information about the volume of the
effect compartment and the receptor concentration in it.
The fitted values of ED50f are rather independent of the
volumes assigned to the effect compartment and the esti-
mates are close to the a priori defined ED50 used in calcu-
lating the target plasma concentrations.
The PK-PD models are based on two sets of experimental
data: the time course of the plasma concentration of a
muscle relaxant and the time course of NMB. The models
simulate, and are applicable only to, the concentrations in
plasma and in the postulated effect compartment. The
amounts or concentrations in the other compartments
and the amount eliminated from the body are not verifia-
ble from the available experimental data. These compart-
ments are included in the current PK-PD model solely to
preserve mass balance and to fit the amounts or concen-
trations of D in compartment1  to the target plasma
amounts or concentrations. A posteriori addition of a large
effect compartment to the standard 3-compartment PK
model alters the simulated amounts or concentrations in
compartment1 and the fit of the standard 3-compartment
model to the target plasma concentrations is lost.Theoretical Biology and Medical Modelling 2005, 2:41 http://www.tbiomed.com/content/2/1/41
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Realization of this fact was the primary reason for the pos-
tulate of a negligibly small effect compartment in the pre-
viously introduced PK-PD model [2]. However, as
demonstrated in the current simulations, a PK-PD model
may include an effect compartment of any volume and
contain a sizable fraction of the injected dose, if the model
is designed a priori and the pharmacokinetic rate con-
stants, including ke1, adjusted so that the amounts in
compartment1  represent as closely as possible the
observed amounts in plasma. The fitting process is similar
to that for fitting a standard pharmacokinetic model to
the observed plasma concentrations. Alternatively and
without prejudging mass transport from plasma to any
compartment, the amounts in plasma may be described
using a multiexponential equation without detriment to
the pharmacodynamic part of the model.
Conclusion
The simulations do not indicate whether a PK-PD model
containing a small or a large effect compartment is more
appropriate. The selection should be based on the results
of prospective clinical experiments. The simulations sug-
gest an optimal experimental design. The study needs to
be conducted with several muscle relaxants. Several doses
of each are selected to produce less than complete NMB,
e.g., NMB10 to NMB90. The experiment needs to answer
the following question: Is the onset time of submaximal
NMB produced by a single muscle relaxant a function of
the level of NMB? If the results with a single muscle relax-
ant show an inverse relationship between the level of
NMB and the onset times, then the model containing a
small volume of the effect compartment and a high recep-
tor concentration is more appropriate. If the onset times
are independent of the magnitude of the submaximal
NMB, then the PK-PD model containing a large volume of
the effect compartment and a low receptor concentration
is more appropriate.
Appendix
The pharmacokinetic part of the model was formulated
with the volume of the effect compartment, Ve, explicitly
incorporated in the model. The following symbols are
used: D for the muscle relaxant and R for the receptors.
The braces denote molar amounts per kg body weight. The
first and second subscript appended to the rate constants
denote the number of the source and the target compart-
ments, respectively. Subscript e denotes the effect com-
partment,  e.g., k1e  denotes the rate constant for the
transport from compartment1 to the effect compartment
and ke1 the transport in the reverse direction. The symbol
{D}e  denotes the free amount of D in the effect
compartment.
DR represents the 1 : 1 complex of D with the receptors
within the effect compartment. The differential equation
for {DR} was derived from the differential equation for
[DR] written in terms of the molar concentrations [D]e,
[R]total, and [DR]. Multiplication of this equation by Ve
converts the concentrations into amounts. The definition
of k1e in terms of ke1, viz., k1e = ke1·(Ve/V1), results from the
postulate of diffusion as the transport mechanism and
implies that the peak concentration of D in the effect com-
partment equals the concentration in compartment1 at the
same moment. The initial conditions at t = 0 are: {D}1 =
dose, and {D}2 = {D}3 = {D}e = {DR} = 0.
The Hill equation for the calculation of NMB from the free
molar concentrations of the muscle relaxant D in the
effect compartment, [D]e, is given by:
where [D]e = peak {D}e/Ve and IC50 = 7·KD = peak [D]e
when Occ = 0.875. The exponent γ was arbitrarily assigned
a value of 4.0.
A different form of the Hill equation was used to fit the
calculated NMB (Eq.1) as a function of the doses produc-
ing the peak [D]e. The modified equation relates NMB to
the injected doses:
The values for the exponent γf and ED50f were derived in
the fitting process.
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Note
1 , where
[Dplasma]i is the molar concentration of D in plasma calcu-
lated from the triexponential equation at time ti, [D1]i is
the molar concentration in compartment1 at the same
time, and n is the number of time points (= 300).
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